← Leaderboards
Charles A Glass
Tega Therapeutics Inc
$1,754,931
Attributed
$1,889,930
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2016–20$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NSF$1,889,930 · 3
By mechanism
—$1,889,930 · 3
Top collaborators
- Susan T Sharfstein1 shared
Grant awards (3)
SBIR Phase II: Development of Bioengineered Anticoagulant Heparin from a Non-Animal Source$1,394,931
· FY2020 · TIP · contact PI
SBIR Phase I: Bioengineered Recombinant Anticoagulant Heparin$225,000
· FY2019 · TIP · contact PI
STTR Phase I: Biomanufacture of Novel Heparan Sulfate Glycosaminoglycans$269,999
· FY2016 · TIP · contact PI